David Crane, MD
Sports Medicine · Chesterfield, MONPI 1144291089
Payments from drug & device makers
What this record shows
The money is spread across several categories — royalties or licence payments (47.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Arthrex accounts for 74.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $5,544 and has fallen 70.2% since, to $1,655 in 2025.
Across 106 payments — averaging $250.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$20K
- Arteriocyte Medical Systems, Inc.$6K
- Elite Orthopedics, LLC$450
- Sportstek Medical, Inc$156
- Antares Pharma, Inc.$108
- Johnson & Johnson$96
- plus $266 from 7 others
What the payments were for
- Royalty or licence$12,57547%
- Consulting fees$1,8007%
- Speaking & faculty fees$5,50021%
- Travel & lodging$3,25312%
- Food & beverage$2,0438%
- Education$1,3745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 64 | $19,680 |
| Arteriocyte Medical Systems, Inc. | 6 | $5,790 |
| Elite Orthopedics, LLC | 9 | $450 |
| Sportstek Medical, Inc | 2 | $156 |
| Antares Pharma, Inc. | 6 | $108 |
| Johnson & Johnson | 5 | $96 |
| Fidia Pharma USA Inc. | 6 | $87 |
| SPR Therapeutics, Inc | 2 | $78 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Amgen | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,545 in reported general payments places this provider in the 85th percentile of 127 sports medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone Cypionate | 61 | $3,390 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 160 | $1,535 |
| Cephalexin | 278 | $488 |
| Gabapentin | 20 | $328 |
| Diazepam | 165 | $186 |
| Tramadol Hcl | 24 | $87 |
| Liothyronine Sodium | 12 | $82 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $81 |
| Clindamycin Hcl | 49 | $74 |
| Metformin Hcl | 13 | $1 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Chesterfield
- Matthew SmithChesterfield$10K
- Matthew BayesChesterfield$6K
- Christopher WolfChesterfield$5K
- Kristin OliverColumbia$209K
- Steven DefrodaColumbia$101K
- Clayton NuelleColumbia$89K
- Justin DragerColumbia$78K
- Derrick KnapikSaint Louis$72K
- Shawn SahotaColumbia$69K
- James StannardColumbia$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.